New drug combo aims to reboot immune attack on head and neck cancer

NCT ID NCT04150900

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding bavituximab to pembrolizumab can help people with advanced head and neck cancer whose tumors have stopped responding to standard immunotherapy. The study enrolled 7 participants and measures how many tumors shrink or disappear. The goal is to see if this combination can re-energize the immune system to fight the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
pembrolizumab and bavituximab (two drugs that help the immune system fight cancer)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced head and neck cancer that has stopped responding to standard immunotherapy.
What could go wrong
This is a very small, early-phase trial with only 7 participants, so results may not apply to everyone. The drugs may cause immune-related side effects, and the combination might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Maryland Medical Center

    Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.